Pluri (NASDAQ: PSTI)
Pluri Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pluri Company Info
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
News & Analysis
Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
Here's Why Pluristem Therapeutics Jumped Over 28% Today
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.
Today's top stories in healthcare and biotech.
Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today
Sinovac, Pluristem, and Synta Pharmaceuticals might all be worth a look today. Let's take a look at the headlines that could move these three stocks.
Why Pluristem Therapeutics Is Poised to Plunge
Market-lagging returns could be written in this 1-Star.
3 Horrendous Health-Care Stocks This Week
Medifast, Questcor, and Pluristem all fell.
Are Short-Sellers Onto Something at Pluristem Therapeutics?
Will this stock make short work of short sellers?
This Week in Biotech: Part 2
A look at the biggest stories this week in biotech and what they mean for investors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.